SOLO2: Final OS Analysis of Maintenance Olaparib in Platinum-Sensitive, Relapsed Ovarian Cancer with BRCA Mutation

May 29-31, 2020; Online at meetings.asco.org/am
Maintenance olaparib increased median OS by more than 1 year vs placebo and was well tolerated over prolonged treatment duration.
Format: Microsoft PowerPoint (.ppt)
File Size: 259 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on patient cases on ovarian cancer treatment

Nicoletta Colombo, MD person default Philipp Harter, MD, PhD person default Alexandra Leary, MD, PhD Released: October 19, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the expert management of ovarian cancer using PARP inhibitors.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Released: October 18, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Virtual presentation by Eloise Chapman-Davis, MD, FACOG, on individualizing care for women with ovarian cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Eloise Chapman-Davis, MD, FACOG Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 15, 2021 Expired: October 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue